Volume 6.12 | Apr 3

Newsletter Issue
Mammary Cell News 6.12 April 3, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
IGF-I Regulates Redox Status in Breast Cancer Cells by Activating the Amino Acid Transport Molecule xC
Scientists showed that Insulin-like growth factor (IGF)-I regulates cystine uptake and cellular redox status by activating the expression and function of xCT in estrogen receptor-positive breast cancer cells by a mechanism that relies on the IGF receptor substrate-1. [Cancer Res] Abstract
Culture and Characterize Mouse Mammary Epithelial Progenitors with Serum-Free EpiCult-B (Mouse). Free Protocols
PUBLICATIONS (Ranked by impact factor of the journal)

Arginine Starvation Impairs Mitochondrial Respiratory Function in ASS1-Deficient Breast Cancer Cells
Scientists demonstrated that prolonged arginine starvation by exposure to ADI-PEG20 (pegylated arginine deiminase) induced autophagy-dependent death of argininosuccinate synthetase 1 (ASS1)-deficient breast cancer cells, because these cells are arginine auxotrophs (dependent on uptake of extracellular arginine). [Sci Signal] Abstract

Synergistic Inhibition of Breast Cancer by Co-Delivery of VEGF siRNA and Paclitaxel via Vapreotide-Modified Core-Shell Nanoparticles
In vitro cell uptake and gene silencing experiments demonstrated that the targeted vapreotide-PLPC/siRNA NPs exhibited significant higher intracellular siRNA accumulation and vascular endothelial growth factor (VEGF) downregulation in human breast cancer MCF-7 cells, compared to those of the non-targeted PEG-PLPC/siRNA NPs. [Biomaterials] Abstract

Mutant p53 Accumulation in Human Breast Cancer Is Not an Intrinsic Property nor Dependent on Structural or Functional Disruption but Is Regulated by Exogenous Stress and Receptor Status
Investigators used immunohistochemistry on cell lines and human breast cancers with known TP53 mis-sense mutations and assessed the effects of each mutation with four structure/function prediction methods. [J Pathol] Abstract

Drug-Repositioning Screening Identified Piperlongumine as a Direct STAT3 Inhibitor with Potent Activity against Breast Cancer
Investigators used a high-throughput fluorescence microscopy search strategy to identify compounds in a drug-repositioning library (Prestwick library) that block ligand-induced nuclear translocation of signal transducer and activator of transcription 3 (Stat3) and identified piperlongumine (PL), a natural product isolated from the fruit of the pepper Piper longum. PL also inhibited mammosphere formation by tumor cells from patient-derived xenografts. [Oncogene] Abstract

Targeting of Preexisting and Induced Breast Cancer Stem Cells with Trastuzumab and Trastuzumab Emtansine (T-DM1)
Primary HER2-overexpressing tumor cells as well as HER2-positive and HER2-negative breast cancer cell lines were treated with T-DM1, and effects on survival, colony formation, gene and protein expression as well as antibody internalization were assessed. [Cell Death Dis] Full Article

Co-Regulation of Genetic Programs by the Transcription Factors NFIB and STAT5
Mammary-specific genetic programs are activated during pregnancy by the common transcription factor STAT5. More than one third of these genes carry NFIB binding motifs that coincide with STAT5 in vivo binding, suggesting functional synergy between these two transcription factors. The role of NFIB in this governance was investigated in mice from which Nfib had been inactivated in mammary stem cells or in differentiating alveolar epithelium. [Mol Endocrinol] Abstract

Nicotine Promotes Apoptosis Resistance of Breast Cancer Cells and Enrichment of Side Population Cells with Cancer Stem Cell-Like Properties via a Signaling Cascade Involving Galectin-3, α9 Nicotinic Acetylcholine Receptor and STAT3
Scientists showed that nicotine induces the expression of galectin-3 (an anti-apoptotic β-galactoside-binding lectin) in a breast cancer cell line and in primary tumors from breast cancer patients. Nicotine-induced up regulation of galectin-3 is due to an increased expression of α9 isoform of nicotinic acetylcholine receptor, which activates transcription factor STAT3 that in turn, physically binds to galectin-3 promoter and induces transcription of galectin-3. [Breast Cancer Res Treat] Abstract

Triptolide-Induced In Vitro and In Vivo Cytotoxicity in Human Breast Cancer Stem Cells and Primary Breast Cancer Cells
Researchers investigated the potential efficacy of the Chinese herbal extract triptolide for the treatment of human breast cancer by measuring the triptolide-induced cytotoxicity in cultures of human primary breast cancer cells and breast cancer stem cells in vitro and in vivo. [Oncol Rep] Abstract


Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib with Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Researchers evaluated buparlisib plus letrozole’s safety, tolerability, and preliminary activity in patients with metastatic estrogen receptor-positive breast cancer refractory to endocrine therapy. [J Clin Oncol] Abstract

Phase II Trial of Everolimus and Carboplatin Combination in Patients with Triple Negative Metastatic Breast Cancer
Investigators aimed to determine clinical benefit rate, that is (complete remission + partial remission + stable disease lasting >=6 months) and the toxicity of everolimus/carboplatin in women with metastatic triple-negative breast cancer. [Breast Cancer Res] Abstract | Full Article

Read White Paper: Increase Success Rate Of Compounds In Toxicity Testing
Regulation of Mammary Epithelial Cell Homeostasis by lncRNAs
The authors first broadly summarize the functions of long noncoding RNAs (lncRNAs) in mammalian development and cancer. Then they focus on what is currently known about the role of lncRNAs in mammary gland development and breast cancer. [Int J Biochem Cell Biol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Sorrento Announces First Patient Dosed in Registration Trial to Evaluate Bioequivalence between Cynviloq and Abraxane
Sorrento Therapeutics, Inc. announced that the first patient has been dosed in the pivotal clinical trial designed to support approval of Cynviloq for the treatment of metastatic breast cancer and non-small cell lung cancer. [Sorrento Therapeutics, Inc.] Press Release

US Oncology Research Joins Corcept Therapeutics’ Phase I Breast Cancer Study
Corcept Therapeutics Incorporated and US Oncology Research announced that two sites affiliated with US Oncology Research will participate in Corcept’s multi-center, Phase I clinical study of mifepristone in combination with chemotherapy drug eribulin (Halaven®) in patients with metastatic or locally advanced unresectable breast cancer. [Corcept Therapeutics Incorporated] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW American Society of Clinical Oncology (ASCO) 50th Annual Meeting
May 30-June 3, 2014
Chicago, United States

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Position in Stem Cell and Cancer (Harvard Medical School)

NEW MSc & PhD Positions – Cell Biology, Neurobiology, Neuroimmunology, Cancer Biology, Computational Biology (Hanyang University)

NEW Postdoctoral Research Associate – Extracellular Microenvironment in Cancer (Institute of Translational Medicine, University of Liverpool)

NEW Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Cancer Cell Signaling (Weizmann Institute of Science)

Junior Faculty Position – Breast Pathology (Northwestern University)

Vice President, Global Medical Affairs – Breast Disease Lead (Celgene Corporation)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Mammary Cell News: Archives | Events | Contact Us